Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates

Jan Källman, Jens Schollin, Claes Schalen, Ann Erlandsson, Erik Kihlström

Abstract

Aims—To study the chemiluminescence response in polymorphonuclear leucocytes (PMNL) at different stages of maturity and the opsonic capacity of sera with defined titres of anti-capsular type III antibodies, after exposure to serotype III group B streptococci (GBS). The influence of GBS type III capsule expression on PMNL chemiluminescence response was also investigated.

Methods—Two clinical isolates of serotype III GBS and two serotype III reference strains which form isogenic variants with high and low amounts of capsule substance, respectively, were used. PMNL and sera were obtained from adult healthy blood donors, full term neonates, and preterm neonates.

Results—PMNL from premature infants showed a significantly lower chemiluminescence response (p<0.0001) than the PMNL from adults and neonates, while the chemiluminescence response with adult, neonatal, and preterm sera gradually diminished. In the presence of a serum pool with a standardised complement value, raised (>10 mg/l), rather than low (<1.0 mg/l) anti-III antibody titres induced a higher chemiluminescence response to the capsule expressing variant. When GBS were cultured at pH 5.0, the bacteria had a higher buoyant density, reflecting decreased expression of capsule substance compared with bacteria grown at pH 7.4. Concomitantly, there was a substantial increase in chemiluminescence response for all isolates cultured at the lower pH, except for the capsule deficient mutant.

Conclusions—PMNL function and opsonic capacity are significantly impaired in neonates and correlate with maturation of the newborn child. The combined defect in cellular and humoral defences in preterm neonates may contribute to their increased susceptibility to GBS infection. Growth conditions for GBS, simulating different in vivo environments, greatly affect capsule expression and resistance to phagocytosis.

(Arch Dis Child Fetal Neonatal Ed 1998;78:F46–F50)

Keywords: phagocytosis; opsonisation; group B streptococci; chemiluminescence; capsule substance

Group B streptococci (GBS) are a major cause of invasive disease in neonates with rates of about 1 per 1000 live births. Low birthweight and prematurity increase the risk of fatal outcome. Serotype III accounts for about two thirds of GBS isolates associated with invasive neonatal disease. In a recently published study it was reported that serotype V has emerged as an important cause of invasive disease in neonates.

Type specific GBS antibody titres, complement activity, and polymorphonuclear leucocyte (PMNL) function are major host defence mechanisms against neonatal GBS infection. For efficient ingestion and killing by PMNL, GBS serotype III strains must be opsonised with antibody and complement. Maximal opsonisation of serotype III strains depends on activation of classic complement pathway, and type specific antibodies. However, opsonisation also depends on alternative complement pathway activation. In general, resistance of GBS to phagocytosis is due to its capsule, a major virulence factor, of which the sialic acid determinants may act to impede the alternative way of complement activation.

The two major receptors for C3 on the surface of human PMNL—CR1 and CR3—are critical to opsonophagocytosis of GBS. It has been suggested that the increased susceptibility of the neonate may depend on a deficient function of the alternative and classic complement pathways.

Abnormal function of PMNL is a major deficit that may increase the risk of bacterial infection in neonates. Previous studies have reported defective oxidative metabolic responses of PMNL from stressed and/or infected neonates while healthy term infants have normal phagocytic and bactericidal activities. Preterm neonates have a decreased phagocytic capacity, as assessed by chemiluminescence response when exposed to opsonised zymosan, compared with term neonates and adults. Three weeks after birth this difference can no longer be seen, suggesting maturational changes in PMNL function. However, previous studies have not compared the phagocytic capacity of PMNL from healthy, term, and preterm neonates towards GBS.

This study was undertaken to examine metabolic burst activity in different age related maturity stages of PMNL, and to determine the opsonic capacity of sera from premature and fullterm neonates in comparison with adults, when exposed to GBS. The influence of GBS type III capsule expression and anti-type III antibodies on PMNL chemiluminescence response was also studied.
Methods

Two clinical isolates of serotype III GBS, VII and IX, obtained from the blood of neonates with clinical sepsis, were used together with two serotype III GBS reference strains. The reference strains U5 and U6 form isogenic variants in the sense that they were derived from the same original clinical isolate, and they express high and low amounts of capsule substance, respectively. Characteristics of these strains have been described before. The strains were cultured at 35–37°C in 4–6% CO₂ on haematin agar plates HEAMP; 4.25% Columbia II agar (Becton Dickinson Microbiology Systems, Cockeysville MD, USA), 3% agar No. 2 (Lab M, UK) and 8.5% horse blood. Bacterial cells used for the chemiluminescence were collected from the plates, washed, and suspended in phosphate buffered saline solution (PBS), pH 7.4 (0.14 M NaCl, 2.7 mM KCl, 12mM Na₂HPO₄, 1.5 mM KH₂PO₄, 0.9 mM CaCl₂ and 0.49 mM MgCl₂). The bacteria were counted in a Bürker chamber and adjusted to 1.6–2.0 x 10⁹ bacteria/ml.

The bacterial strains were inoculated in 5 ml Todd–Hewitt broth (Becton Dickinson Microbiology Systems) adjusted to pH 5.0 and pH 7.4, respectively, and cultured overnight with shaking at 35–37°C and 4–6% CO₂. From this overnight culture, 50 µl was withdrawn, incubated, and cultured overnight a second time at a different pH, as described above. The strains were washed with H₂O and pelleted by centrifugation at 2000 × g, washed once, counted in a Bürker chamber, and resuspended in PBSgg to a concentration of 3–6 x 10⁹ cells/ml. More than 95% of the cells were PMNL and previous staining with trypan blue of PMNL prepared by the same method have shown 95% viability.

Pooled human serum from 10 healthy blood donors of blood group AB Rh+ (AS) was used in opsonisation experiments in combination with either AG, NG, or PG. Sera from 13 full term neonates (NS) were used in opsonisation experiments in combination with either AG or NG, and sera from five premature children (PS) were used together with AG. The pooled adult human serum had concentrations of C₃/C₄, IgG, IgA, IgM as well as IgG subclasses within normal limits and showed normal complement dependent haemolytic activity with antibody coated sheep erythrocytes. The albumin concentration was normal (37 g/l). The acute phase proteins orosomucoid and C reactive protein were not increased.

The concentrations of C₃c and GBS type specific antibodies in eight of the NS and four of the PS are shown in table 1. C₃c is a split product and reflects total C₃ concentration and the reference range is 0.55–1.22 g/l. The C₃c concentrations were determined by immunodiffusion using Mancini gel (Mannheim, Germany) and IgG antibodies against GBS capsular antigens were estimated in an enzyme immunoassay test.

To examine the role of anti-type III antibodies in opsonisation, six sera with high (>10 mg/l) and six with low (<1.0 mg/l) concentrations of serotype III IgG antibodies were used. The sera were heat inactivated for 1 hour at 56°C and supplemented with equal amounts, 1:1, of serum, with no detectable titres of antibodies against the GBS serotypes Ia, Ib, II or III. With this external complement source the concentration of C₃c was 1.47 g/l in each of the 12 sera.

A luminometer (LKB Wallac 1251, Turku Finland), connected to a Probyte midi computer, allowed up to 25 tests to be carried out in each experiment. A phagocytosis programme was used for measurements and calculations of data. To each test tube (LKB AB, Bromma, Sweden, No. 2174-086) the following was added: 200 µl PBS, 100 µl serum, 100 µl PMNL, 50 µl 10⁶ M Luminol (Sigma), and 50 µl of the bacterial suspension. The final ratio of bacteria:PMNL was about 200:1.

The chemiluminescence assays were run within 3 hours of collection of blood samples. The measurements were started within 2 minutes of adding the bacteria to the reaction. The assays were performed at 37°C with continuous shaking of the test tubes. Except for a few reactions with premature serum every sample was run in duplicate and measured at least every 194 seconds for about 25 minutes.

The chemiluminescence activity was recorded as a response curve over time and the peak value (mV) was noted. The maximal rate constant was calculated as a function of chemiluminescence (mV) and time (seconds)—mV/sec. To control the interassay variations, a reference reaction using GBS strain U6, pooled
OPSONIC ACTIVITY OF SERA

Phagocytosis has both a cellular component, exerted by PMNL, and a humoral component via antibodies and complement. Our aim was to discriminate between these two components and to study the contribution of each in the potential phagocytic defects against GBS in neonates. Therefore, the chemiluminescence response of PMNL from adults, full term, and preterm neonates exposed to GBS in vitro was recorded using a standardised humoral component. Pooled adult human sera with 1.6 mg/l of anti-serotype-III IgG antibodies and 1.00 g/l of C3c was added to each set of PMNL. This antibody concentration is below the proposed protective level and C3c is within normal values.15

Premature PMNL showed significantly lower chemiluminescence response (p<0.0001) when exposed to GBS than adult and full term PMNL (fig 1). This was true for all four GBS strains tested. However, there was no significant difference in chemiluminescence response of PMNL from adults and full term neonates. The capsule deficient mutant U6 induced the highest chemiluminescence response in all three sets of PMNLs—about four times the response of the capsule expressing variant U5.

RESULTS

Phagocytic activity of PMNL from adults, full term, and preterm neonates

Phagocytosis has both a cellular component, exerted by PMNL, and a humoral component via antibodies and complement. Our aim was to discriminate between these two components and to study the contribution of each in the potential phagocytic defects against GBS in neonates. Therefore, the chemiluminescence response of PMNL from adults, full term, and preterm neonates exposed to GBS in vitro was recorded using a standardised humoral component. Pooled adult human sera with 1.6 mg/l of anti-serotype-III IgG antibodies and 1.00 g/l of C3c was added to each set of PMNL. This antibody concentration is below the proposed protective level and C3c is within normal values.15

Premature PMNL showed significantly lower chemiluminescence response (p<0.0001) when exposed to GBS than adult and full term PMNL (fig 1). This was true for all four GBS strains tested. However, there was no significant difference in chemiluminescence response of PMNL from adults and full term neonates. The capsule deficient mutant U6 induced the highest chemiluminescence response in all three sets of PMNLs—about four times the response of the capsule expressing variant U5.

Onopsonic activity of sera

To standardise the cellular component of phagocytosis, PMNL from healthy adults were incubated in the presence of GBS, and with sera from adults, full term, and preterm adult human sera and adult blood donor PMNL (AG) was included in each experiment. The CL response was expressed as the ratio between the test reaction and the reference reaction.

Statistical analysis for comparison between groups was performed using paired t test. All analyses were performed using StatView.

Figure 1 Chemiluminescence response (mV/second) of adult PMNL to GBS in the presence of sera from adult blood donors, full term, or preterm neonates. Bars represent mean (SD) of ratio of four to 11 individuals.

Figure 2 Comparison of chemiluminescence responses (mV/second) of adult PMNL to GBS in the presence of sera from adult blood donors, full term, or preterm neonates. Bars represent mean (SD) of ratio of 2 to 13 individuals with at least 2 experiments carried out on each serum sample.

EFFECT OF GBS CULTURE CONDITIONS AND CAPSULE EXPRESSION ON CHEMILUMINESCENCE

Capsule expression of GBS significantly impairs phagocytosis, as assessed by chemiluminescence response (figs 1 to 3). Furthermore, growing GBS at pH 4.5 inhibits capsule expression15 and increases the buoyant density of the bacteria.15 When GBS strains U5, U6, VII and IX were grown at pH 5.0, they showed...
Table 1  IgG antibodies against GBS serotypes Ia, Ib, II and III in mg/l and concentration of complement component C3c in sera of adults, premature, and full term neonates

<table>
<thead>
<tr>
<th>Serum</th>
<th>No</th>
<th>Ia*</th>
<th>Ib*</th>
<th>II*</th>
<th>III*</th>
<th>C3c†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult</td>
<td></td>
<td>0.75</td>
<td>1.3</td>
<td>0.55</td>
<td>1.6</td>
<td>1.00</td>
</tr>
<tr>
<td>Full term neonatal</td>
<td></td>
<td>0.5</td>
<td>0.7</td>
<td>0.5</td>
<td>0.8</td>
<td>1.06</td>
</tr>
<tr>
<td>Preterm neonatal</td>
<td></td>
<td>0.8</td>
<td>5.9</td>
<td>1.7</td>
<td>10.2</td>
<td>1.17</td>
</tr>
<tr>
<td>Adult Pooled</td>
<td></td>
<td>28</td>
<td>0.5</td>
<td>0.7</td>
<td>0.5</td>
<td>1.06</td>
</tr>
<tr>
<td>Full term neonatal</td>
<td></td>
<td>29</td>
<td>0.6</td>
<td>&lt;0.1</td>
<td>0.7</td>
<td>0.84</td>
</tr>
<tr>
<td>Preterm neonatal</td>
<td></td>
<td>50</td>
<td>0.8</td>
<td>3.3</td>
<td>1.2</td>
<td>5.4</td>
</tr>
<tr>
<td>Adult</td>
<td></td>
<td>57</td>
<td>0.8</td>
<td>4.3</td>
<td>1.6</td>
<td>6.6</td>
</tr>
<tr>
<td>Full term neonatal</td>
<td></td>
<td>61</td>
<td>0.7</td>
<td>0.6</td>
<td>0.5</td>
<td>0.6</td>
</tr>
<tr>
<td>Preterm neonatal</td>
<td></td>
<td>520</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Adult</td>
<td></td>
<td>542</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Full term neonatal</td>
<td></td>
<td>541</td>
<td>1.0</td>
<td>2.1</td>
<td>1.6</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Preterm neonatal</td>
<td></td>
<td>61</td>
<td>0.6</td>
<td>0.5</td>
<td>0.3</td>
<td>&gt;0.1</td>
</tr>
<tr>
<td>Adult</td>
<td></td>
<td>57</td>
<td>1.3</td>
<td>1.2</td>
<td>0.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Full term neonatal</td>
<td></td>
<td>50</td>
<td>0.8</td>
<td>3.3</td>
<td>1.2</td>
<td>5.4</td>
</tr>
<tr>
<td>Preterm neonatal</td>
<td></td>
<td>29</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>Adult</td>
<td></td>
<td>28</td>
<td>0.8</td>
<td>4.3</td>
<td>1.6</td>
<td>6.6</td>
</tr>
<tr>
<td>Full term neonatal</td>
<td></td>
<td>24</td>
<td>0.8</td>
<td>3.3</td>
<td>1.2</td>
<td>5.4</td>
</tr>
<tr>
<td>Preterm neonatal</td>
<td></td>
<td>23</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
<td>&lt;0.1</td>
</tr>
</tbody>
</table>

* Titres of GBS serotype specific IgG antibodies expressed in mg/l. † Concentration of complement C3c in g/l; reference range 0.55-1.22 g/l.

Discussion

GBS carriage is common in pregnant women, hence the ability of neonates to resist invasive GBS infections is of major importance for survival. As prematurity is a well known major risk factor for developing GBS disease, knowledge of the potential of neonates at various gestational ages to cope with GBS is of clinical interest.

We found that the chemiluminescence response of PMNL from premature infants compared with that of full term neonates was greatly depressed, whereas the response of the former did not differ significantly from that of healthy adults. PMNL from healthy newborns have been shown to exhibit normal phagocytosis of opsonised particles as well as particles that required no opsonization. On the other hand, stressed neonates and premature children generally show depressed chemiluminescence responses, and this deficient PMNL function in the premature infants may persist for up to two months after birth. The mechanism for this is unknown, but one possibility might be a defective degranulation or low amount of enzymes in the primary and secondary granulae of PMNL. The PMNL of premature infants also show decreased chemotactic and adhesive capacities—the latter due to failure to upregulate surface expressed adhesion glycoproteins, which might also impair the ability to ingest GBS. Furthermore, release of the chemoattractant interleukin-8 from neonatal monocytes stimulated with GBS is less than the release from adult monocytes. Another possibility might reside in rigid contractile cytoskeletal elements in premature PMNL with subsequent decreased internalisation into phagocytic vacuoles.

In our study we were able to show an impaired chemiluminescence response of PMNL in the presence of neonatal and premature sera compared with that in adult sera. This difference between adult and full term serum samples might explain why term children might be prone to severe invasive GBS infections. Once again premature infants are disadvantaged as sera from these children show inferior opsonic capacity to those of full term children. This difference was most pronounced for the isolate U6 which is the isogenic variant with a low amount of capsular substance. The type III capsular polysaccharide inhibits the alternative pathway complement activation by preventing C3 deposition on the surface of GBS. Therefore, complement activation might be of major importance for opsonisation of GBS with low amounts of capsule substance. Furthermore, when serum was heat inactivated and no external complement was expressed by GBS strains grown at pH 5 and pH 7.4. The chemiluminescence response is expressed as the ratio between the responses of strain U6 grown at pH 7.4. Bars represent mean (SD) of six experiments. *Density of strains, as determined by Percoll gradient centrifugation.

Figure 3 Chemiluminescence response (mV/second) of adult PMNLs in the presence of sera from adult blood donors with high (>10 mg/l) or low (<1.0 mg/l) titres of GBS serotype III antibodies. GBS serotype III variants U5 and U6 express high and low amounts of capsule substance, respectively. Plots represent mean (SD) of 12 experiments.

Figure 4 Chemiluminescence response (mV/second) of adult blood from donor PMNLs and pooled human adult sera exposed to different GBS strains grown at pH 5 and pH 7.4. Bars represent mean (SD) of six experiments. *Density of strains, as determined by Percoll gradient centrifugation.
added, there were no chemiluminescence response. In the present study we did not investigate the role of different complement factors in the opsonisation of GBS strains. However, concentrations of C3c, which reflect total concentration of C3 as the pivotal protein site of convergence of the classic and alternative complement pathways, were within normal the range.

Decreased capsular substance, expressed as high buoyant density, could also be seen when GBS was cultured at pH 5.0, compared with that at pH 7.4. The substantial increase in chemiluminescence response for bacterial strains cultured at the lower pH, except for the capsule deficient mutant, may reflect increased opsonic capacity by complement activation in the absence of the capsule. The expression of the capsular substance as dependent on the pH value might reflect a virulence factor for GBS. In genital tracts with a low pH, the GBS will downregulate capsule substance expression. This might also lead to unmasking of surface exposed lipotheichoic acid, various surface proteins, or some other molecule(s) which may act as adhesions and thereby increase genital colonisation. When GBS enter the bloodstream, due to the neutral pH, the bacteria will switch on capsular expression conferring enhanced resistance to phagocytosis.

The relation between low concentrations of antibody to the capsular polysaccharide of type III GBS in maternal sera and the risk of invasive infection in neonates by GBS has been shown before. We have also shown that sera with high titres of antibody to capsule substance had a higher chemiluminescence response than sera with low titres and this might therefore protect against invasive infection.

In conclusion, the defect PMNL function and opsonic capacity against GBS in preterm neonates calls for an aggressive clinical approach in these cases. The need for vaccine or highly concentrated type specific preparations for these children is therefore obvious. It is also extremely important to identify mothers at high risk of transmitting GBS to their offspring. The study also shows that the expression of capsular substance determines the ability to opsonise GBS successfully by complement or serotype III antibody. Finally, the expression of the capsular substance as dependent on different growth conditions may help us to understand better the pathogenic mechanisms leading to invasive GBS disease.

This study was supported by grants from the Research Committee of Örebro County, Örebro Medical Centre Foundation, King Gustav V’s 80-year Foundation, Börje Vahlén’s Foundation and Sven Johanssons memorial Foundation.

We acknowledge the kind gift of GBS reference strains from Stellan Häkansson.

Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates

Jan Källman, Jens Schollin, Claes Schalèn, Ann Erlandsson and Erik Kihlström

Arch Dis Child Fetal Neonatal Ed 1998 78: F46-F50
doi: 10.1136/fn.78.1.F46

Updated information and services can be found at:
http://fn.bmj.com/content/78/1/F46

These include:

References
This article cites 27 articles, 9 of which you can access for free at:
http://fn.bmj.com/content/78/1/F46#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Child health (1515)
- Immunology (including allergy) (393)
- Infant health (857)
- Neonatal health (928)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/